Cargando…
Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series
INTRODUCTION: No published clinical trial data are available to inform the use of enzyme replacement therapy (ERT) in patients with the severe (neuropathic) phenotype of mucopolysaccharidosis II (MPS II). Current guidelines recommend ERT administered intravenously be used on a trial basis in this po...
Autores principales: | Lampe, Christina, Bosserhoff, Ann-Kathrin, Burton, Barbara K., Giugliani, Roberto, de Souza, Carolina F., Bittar, Camila, Muschol, Nicole, Olson, Rebecca, Mendelsohn, Nancy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158409/ https://www.ncbi.nlm.nih.gov/pubmed/24596019 http://dx.doi.org/10.1007/s10545-014-9686-7 |
Ejemplares similares
-
Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014) -
The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020) -
Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023) -
Impact of ERT and follow-up of 17 patients from the same family with a mild form of MPS II
por: Stephan, Bruno de Oliveira, et al.
Publicado: (2022) -
Evaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
por: Violano, R, et al.
Publicado: (2013)